Print page Share page

About ARIAD's investigator-sponsored trials.

ARIAD supports independent research aimed at advancing clinical and scientific understanding of our products. All proposals submitted to ARIAD undergo scrutiny by a team of professionals for scientific merit and alignment with our research goals. If you are interested in submitting a research proposal, please contact us at IST@ariad.com.

Ponatinib is being studied in several investigator sponsored trials.

Phase 2 Study of Ponatinib and Hyper-CVAD in Ph+ and/or BCR-ABL Positive ALL

Study Design: Non-randomized, open-label, single-center
Patients: Patients with Ph+ ALL and/or BCR-ABL positive ALL who were previously untreated or who previously received 1–2 courses of chemotherapy with or without other TKIs
Purpose: To learn if intensive chemotherapy combined with ponatinib, followed by maintenance therapy, can help to control ALL with the Ph chromosome and/or BCR-ABL. The safety of this treatment will also be studied.
Location: MD Anderson Cancer Center, Houston, TX

Phase 2 Study of Ponatinib in Newly Diagnosed Accelerated Phase CML Patients

Study Design: Non-randomized, open-label, single-center
Patients: Treatment-naïve patients diagnosed with CML within six months prior to enrollment
Purpose: To learn if ponatinib as initial therapy can help control CML in chronic phase. The safety of ponatinib in this setting will also be studied.
Location: MD Anderson Cancer Center, Houston, TX

Phase 2 Front-line Treatment of Adult Affected of Philadelphia+ Acute Lymphoblastic Leukemia (ALL) With Ponatinib.

Study Design: Non-randomized, open-label, multi-center
Patients: Treatment-naïve patients diagnosed with Ph+ALL elderly (over 60 years old) or unfit for intensive chemotherapy program or stem cell transplant
Purpose: To learn if ponatinib as initial therapy can help in Ph+ALL without intensive chemotherapy, but in combination with steroids only and IT (if CNS is involved). The safety of ponatinib in this setting will also be studied.
Location: Department of Hematology and Oncology "Seràgnoli", "Sant'Orsola-Malpighi" University Hospital of Bologna and collaborative group of clinical centers Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) in Italy

Phase 2 Study of Ponatinib in Advanced Non-Small Cell Lung Cancer with RET Translocations

Study Design: Non-randomized, open-label, multi-center
Patients: Patients with advanced non-small cell lung cancer (NSCLC) with a RET translocation
Purpose: To evaluate ponatinib as a RET inhibitor in patients with NSCLC
Location: Massachusetts General Hospital, Boston, MA; University of California, Irvine, CA; Ohio State University, Columbus, OH; University of Maryland Medical Center Baltimore, MD ; Karmanos Cancer Institute Detroit, MI

Phase 2 Study of Ponatinib in Patients with Lung Cancer Preselected Using Different Candidate Predictive Biomarkers

Study Design: Non-randomized, open-label, single-center
Patients: Patients with advanced non-small cell lung cancer (NSCLC, stage IV) with predictive biomarkers such as FGFR1 or RET genetic aberrations (but EGFR- and ALK- negative)
Purpose: To evaluate prevalence of biomarkers and ponatinib activity in preselected patients with NSCLC. The safety of ponatinib in this setting will also be studied.
Location: University of Colorado Cancer Center

Phase 2 Study of Ponatinib in Advanced Medullary Thyroid Cancer

Study Design: Non-randomized, open-label, single-center
Patients: Patients with localized or metastatic unresectable medullary thyroid cancer
Purpose: To determine the objective overall response rate of patients with MTC to ponatinib
Location: National Cancer Institute, Bethesda, Maryland

Phase 2 Study of Ponatinib with Cytarabine as Consolidation Therapy in Patients with FLT3-ITD AML

Study Design: Non-randomized, open-label, multi-center, dose-escalation phase 1–2 trial
Patients: Patients with acute myeloid leukemia FLT3-ITD positive in first complete remission
Purpose: To assess the safety and efficacy of ponatinib in combination with high- or intermediate-dose cytarabine as consolidation therapy for patients with intermediate-risk cytogenetic FLT3-ITD AML
Locations: Hôpitaux de Versailles, Hôpital Mignot, France; approximately 45 ALFA and GOELAM clinical centers

Phase 1 Study: MATCHPOINT MAnagement of Transformed CHronic myeloid leukaemia: POnatinib and INTensive chemotherapy: a dose-finding study

Study Design: Non randomized, open label, multi-center
Patients: Patients in chronic myeloid leukemia blast crisis (BP-CML)
Purpose: To determine the optimal dose combination of ponatinib with conventional chemotherapy that is both tolerable and shows sufficient efficacy to take forward into phase 2/3 for the treatment of chronic myeloid leukemia in blastic transformation.
Locations: Cancer Research UK Clinical Trials Unit (CRCTU) University of Birmingham and other NCI centers in CML Working Group in the U.K.

Phase 2 Ponatinib Hydrochloride in Treating Patients with Advanced Biliary Cancer with FGFR2 Fusions (A pilot study)

Study Design: Non-randomized, open-label, single-center
Patients: Patients with metastatic biliary cancer, that have genetic alterations (fusions) in a gene known as fibroblast growth factor receptor 2 (FGFR2)
Purpose: To determine the clinical benefit rate in biliary cancer patients treated with ponatinib
Locations: Hôpitaux de VMayo Clinic, Arizona

Phase 2 randomized study to evaluate the feasibility of sequential administration of TKI inhibitor ponatinib with standard chemotherapy in younger patients aged 18 to 60 years with acute myeloid leukemia

Not yet open for enrollment
Study Design: Randomized (randomized 2:1 to Ponatinib or no Ponatinib), open label, multicenter
Patients: Patients diagnosed with acute myeloid leukemia after first course of intensive induction therapy and tested FLT3-positive
Purpose: To evaluate safety measures when Ponatinib is sequentially given after intensive chemotherapy for high risk patients. It will also provide preliminary information about efficacy of the combination.
Locations: NCRI Cardiff Experimental Cancer Medicine Center and other centers in AML Working Group in the U.K.

Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma (A pilot study)

Not yet open for enrollment
Study Design: Randomized, open-label, multicenter
Patients: Patients with recurrent or persistent endometrioid endometrial cancer, with FGFR2 activating mutation
Purpose: To evaluate response rate in patients with endometrial cancer treated with ponatinib. The safety of ponatinib in this setting will also be studied.
Locations: Washington University School of Medicine, Division of Gynecologic Oncology; Ohio State University Medical Center, Gynecologic Oncology

Phase 2 study of ponatinib for advanced cancers with genomic alterations in fibroblastic growth factor receptor (FGFR) and other genomic targets (KIT, PDGFRα, RET, FLT3, ABL1)

Not yet open for enrollment
Study Design: Randomized, open-label, multicenter
Patients: Patients with refractory metastatic solid tumor or chronic hematological malignancy with activating genomic alterations in FGFR (mutations, fusions or amplifications) or activating genomic alterations in KIT, platelet-derived growth factor receptor alpha (PDGFRα), ret proto-oncogene (RET), ABL proto-oncogene 1, non-receptor tyrosine kinase (ABL1) and fms-related tyrosine kinase 3 (FLT3)
Purpose: To evaluate the response to ponatinib in patients with fibroblast growth factor receptor (FGFR) altered cancers, and tumors comprising other genomic targets.
Locations: Ohio State University Comprehensive Cancer Center; University of Michigan Cancer Center

Phase 3 Study to Evaluate the Impact of Switching CML Patients Treated with a First-line Tyrosine Kinase Inhibitor to Ponatinib – SPIRIT 3

Not yet open for enrollment
Study Design: Randomized, open-label, multicenter
Patients: Adult patients with chronic-phase CML diagnosed within three months and previously untreated for CML with any TKI therapy
Purpose: To compare the efficacy and cost-effectiveness of front-line treatment of imatinib versus nilotinib in chronic myeloid leukemia (CML) with switching to ponatinib upon suboptimal response or treatment failure
Locations: Newcastle University and multiple centers in NCRI CML Working Group in the U.K.

Investigator-sponsored trials

View all open clinical trials at ClinicalTrials.gov.

More
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue